



3FW

PATENT
ATTORNEY DOCKET NO. 50304/138001

Certificate of Mailing: Date of Deposit: September 25, 2006

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Christine E. Fort
Printed name of person mailing correspondence

Christine E. Fort
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Piet HERDEWIJN et al.	Confirmation No.:	6995
Serial No.:	10/598,535	Art Unit:	Not Yet Assigned
Filed:	September 1, 2006	Examiner:	Not Yet Assigned
Customer No.:	21559		
Title:	PHOSPONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed. Copies of an International Search Report, a Written Opinion, and an International Preliminary Examination Report are also enclosed.


Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

If there are any charges or any credits, please apply them to Deposit Account No.

03-2095.

Respectfully submitted,

Date: 25 - Sep - 2006



James D. DeCamp
Reg. No. 43,580

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045


Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50304/138001
	Serial No.	10/598,535
	Applicant	HERDEWIJN et al.
	Filing Date	September 1, 2006
	Group	Not Yet Assigned
	IDS Filed	September 25, 2006

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Dujardin et al. "Asymmetric Endoselective [4+2] Heterocycloadditions of Styrene Dienophiles with Chiral Benzylidenepyruvic Esters. Total Synthesis of (-)-O-Dimethylsugiresinol," <i>Tetrahedron Letters</i> 38 (9): 1555-1558 (1997).					
	Griengl et al. "Phosphonoformate and Phosphonoacetate Derivatives of 5-Substituted 2'-Deoxyuridines: Synthesis and Antiviral Activity," <i>J. Med. Chem.</i> 31 :1831-1839 (1988).					
	Kim et al. "Regiospecific and Highly Stereoselective Electrophilic Addition to Furanoid Glycals: Synthesis of Phosphonate Nucleotide Analogues with Potent Activity against HIV," <i>J. Org. Chem</i> 56 : 2642-2647 (1991).					
	Lambert et al. "Synthesis and Antiviral Activity of Phosphonoacetic and Phosphonoformic Acid Esters of 5-Bromo-2'-deoxyuridine and Related Pyrimidine Nucleosides and Acyclonucleosides," <i>J. Med. Chem</i> 32 : 367-374 (1989).					
	McNulty et al. "On the direct 2,3-hydroxyl-group differentiation of tartaric acid esters," <i>Tetrahedron Letters</i> 43 : 3857-3861 (2002).					
	Wu et al. "Deoxythreosyl Phosphonate Nucleosides as Selective Anti-HIV Agents," <i>J. Am. Chem. Soc.</i> 127 : 5056-5065 (2005).					
	International Search Report issued in PCT/BE2005/000032 (dated August 30, 2005)					
	Written Opinion of the International Searching Authority issued in PCT/BE2005/000032 (dated August 30, 2005)					
	International Preliminary Report on Patentability issued in PCT/BE2005/000032 (dated May 23, 2006)					

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	